4. Neuromuscular blocking & anti-cholinesterases Flashcards

(88 cards)

1
Q

Rocuronium

Type
ED  95 
Intubating dose
Time to 95% depression TOF
Time to recovery of 1st TOF

Reversed by what (& group)

Solubility water / fat
Excretion
Mtabolite

A

aminosteroid

develop

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is ED 95

What is the ED 95 of common NMB

Most potent

Roc, sux, vec, mivac, citrac pan

A

Dose required to depress the twitch height by 95%

The ED95 (mg/kg) of the commonly used neuromuscular blocking agents are:

vecuronium: 0.04 (0.1 mg/kg induction, 2.5x the ED95)
cisatracurium: 0.04 (0.2 mg/kg induction, 5x the ED95)

Pancuronium: 0.07 (0.1 mg/kg induction, 1.4x the ED95)

mivacurium: 0.08 (0.15 mg/kg induction, 2x the ED95)
suxamethonium: 0.27 (1mg/kg induction, 3-4x the ED95)
rocuronium: 0.31 (0.6-1 mg/kg induction, 1.9 to 3.2x the ED95)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Prolong non depol

A

delete and put into 1 card

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Suxamethonium side effects

A
  1. myalgia ranges from 1.5 - 85%
    - female
    - ambulatory surgery
    - like DOMS

no corel to fasiculations

  1. Transiet pottasium rise
    - dangerous burns
    - high SC injury
    safe <48h from injury
  2. Prolong block
    - phase 2
    genetic / acquired deficiency plas cholinesterase
  3. Sux apneoa 1:1800
  4. Anaphylaxis
    1: 1000.
  5. MH
    1: 45000 -100000
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Adequate reversal

A

Ability to hold the head off the pillow for five seconds

Generation of tidal volumes of 15 ml/kg

Four equal twitches on train of four count

T4:T1 ratio of 0.9

PTC
used when too deep to see TOF
stimulation at 50Hz 5s mobilise enough presynaptic acetylcholine allow assessment deep block
ost-tetanic count of >15 approximates two twitches on the train-of-four count

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Organophosphate poisoning

A

Pesticides and ‘chemical nerve agents’

Irreversibly bind to acetylcholinesterase (AChE) in the synaptic clefts of nerve termin

Form Covalent bond serine site

prevents bdown of Ach

Overstimulation of muscarinic and nicotinic ACh receptors in the autonomic nervous system
Overstimulation of ACh receptors in the central nervous system
Overstimulation of ACh receptors at the neuromuscular junction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

NDMR
How work
Where

Classified & ex

A

Non-depolarising muscle relaxants (NDMRs) inhibit the actions of acetylcholine at the neuromuscular junction by binding competitively to the α-subunit of the nicotinic acetylcholine receptor on the post-junctional membrane.
They also have effects on prejunctional receptors that serve to modulate acetyl choline release. Blockade of the receptors are thought to be responsible for fade during tetanic stimululi or train of four.

Aminosteroid
vecuronium, rocuronium and pancuronium.

benzylquinolinium:
atracurium, mivacurium and tubocurarine.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

trac metabolic pathway

Temp + pH

A

pathway and undergoes ester hydrolysis accounting for 60% of its metabolism, and Hofmann elimination, which is temperature and pH dependent.
As pH and temperature decrease, Hofmann elimination also decreases and the reverse applies to and increase in temperature and pH.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Hyoscine

Properties

BBB - hydrobromide v butylbromide
S/E
Use

Repeat dosing

A

The antimuscarinic drug hyoscine (scopolamine) is a naturally occurring belladonna alkaloid with smooth muscle relaxant (antispasmodic) and antisecretory properties.

Hyoscine hydrobromide does cross the blood-brain barrier and so may cause sedation or drowsiness (hyoscine butylbromide does not cross the BBB) and it has a central antiemetic action (useful in motion sickness).

Repeated administration of hyoscine hydrobromide leads to accumulation, which occasionally can paradoxically result in an agitated delirium.

The central anticholinergic syndrome (excitement, ataxia, hallucinations, behavioural abnormalities and drowsiness) is a side effect of its use.

Pupillary dilatation is a feature, but a tachycardia (heart rate >100/minute) is rarely seen.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Atracurium

whats it made up of

tube dose

metab
affect how

metabolites

problems

A

benzylisoquinolinium
10 stereoisomer
4 chiral

intub dose 0.5mg kg - moderate duration

Body temp <40% hoffman -> Laudenosine - neuro side effects
Inc w/ inc temp & temp

Remainder - ester hydrolysis
reduced by alkalosis and enhanced by acidosis

both metabolisms yield laudonise

His release - reflex tachy

Stored at 2-8° (RT - activity sml % per month)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Elimination of a hypothetitical NMB w/ 3 quaterny n & Hep extraction ratio .25

A

Likely fitered kidny & not reabsorbed

Would be polarised - Low Vd
Unlikely ester - not tfer tissues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Mivacurium

Metabolism

A

Mivacurium with plasma cholinesterase deficiency
Heterozygous - 50% prolongation has been shown.
Homozygous - extend to 2 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Prolong / potentiate NDMR

A
Hypokalaemia
Hypocalcaemia
Hypermagnesaemia
Metabolic alkalosis
Respiratory acidosis and
Hypothermia. enzyme activity decreased 

drugs
Antibiotics such as streptomycin, polymyxin and neomycin
Cocaine, procaine and lidocaine and
Lithium due to its hypokalaemic effect.

Amitryptilline ; TCA - closed channel block

Verapamil - open channel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Vecuronium

A

Aminosteroid
10 mg of powder in mannitol and sodium hydroxide
unstable soln

Monoquaternary aminosteroid

Competitive inhibitor @ alpha subunit Nic AchR

Intubating dose 0.1 mg/kg - in 120 seconds.
(

Most CVstable
Least rel His
Lowest anaphylaxis

3, 3-17 and 17 dihydroxyvecuronium. 3 hydroxyvecuronium is an active metabolite
accumulate in renal failure.

Sim structure Roc ; Panc
more lip sol vs panc)

(panc releases norepi)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Suxamethonium

A

a dicholine ester which is equivalent to two acetylcholine molecules joined together

side effects include:

Bradyarrhythmias
nodal brady secondary to direct nodal musc stim
Myalgia
Hyperkalaemia
Raised intraocular pressure
Anaphylaxis
Malignant hyperthermia.

Doesnt cause increased reflux - increases tone of LOesSph

plasma cholinesterase (pseudo-cholinesterase) and only 20% of the administered dose reaches the neuromuscular junction.

A large total dose or repeated dosages of suxamethonium can cause a phase II block.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Sugammadex

A

Sugammadex is licensed for immediate reversal of rocuronium-induced neuromuscular blockade at a dose of 16 mg/kg.

modified gamma-cyclodextrin
encapsulate aminosteroid
A concentration gradient then forms which pulls the NMB molecules from the neuromuscular junction in the tissues back into the bloodstream.
Though it is most effective in reversing rocuronium, it will also reverse vecuronium. It has been shown also to bind weakly to pancuronium.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Neostigmine -

what is it
use

Action
direct or indirect

Type of molecule
motion in body

Onset + duration

Excretion

A

Neostigmine is an acetylcholinesterase inhibitor which is used to reverse a non-depolarising block and is used in the management of myasthenia gravis.

Inhibition of the acetylcholinesterase enzyme increases the concentration of acetylcholine at the neuromuscular junction. It also directly stimulates acetylcholine receptors in skeletal muscle and may cause a depolarising block in overdosage (not non-depolarising block).

It is a quaternary ammonium compound and poorly crosses the blood-brain barrier and has few central nervous system side effects.

When given intravenously it is active within one minute and lasts 20 - 30 minutes.

It is excreted renally and is mostly unchanged and has an elimination half life of 50 - 90 minutes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Suggamadex is a

Recommended for us with
in what patient group

How does it work

A

Sugammadex (Bridion), a modified gamma-cyclodextrin,

Rocuronium- or vecuronium-induced moderate or deep muscle relaxation in adult (including elderly) patients and reversal of rocuronium-induced moderate muscle relaxation in paediatric patients.

Mechanism of action of sugammadex is to encapsulate rocuronium to provide for a rapid reversal of residual neuromuscular blockade.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Resistance to NDMR

a/w

x4

A

1 Burns

2 Antiepileptic drugs

3 Intracranial lesions

4 Hemiplegia (when neuromuscular function is monitored on the affected side).

Long term phenytoin therapy shortens the duration of action of long acting muscle relaxants by 50%. Burn victims and patients suffering from stroke may be resistant to non-depolarizing NMBDs (likely due to extrajunctional receptors).

Hypothermia is associated with prolongation (not resistance) of neuromuscular blockade.

Patients with myasthenia gravis are extremely sensitive to non-depolarising neuromuscular blockade.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Atracurium

Type compound
MOA

Cross placenta?
Why

Release

Metbolism

A

Atracurium is a benzyl isoquinolinium ester compound. It is a competitive antagonist at the neuromuscular junction preventing acetylcholine from binding.

Like all non-depolarising muscular blockers it is a highly charged quaternary compound. It is therefore unable to cross the placenta easily.

Atracurium can cause histamine release. This is reduced by using the enantiopure cis-atracurium.

About 60-90% of atracurium is metabolised by ester hydrolysis by non-specific esterases.

It also undergoes non-enzymatic breakdown (Hofmann elimination). The atracurium molecule combines with a base which catalyses a reaction to produce the metabolites, quaternary monoacrylate and laudanosine.

The Hofmann elimination is pH and temperature dependent.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Gantacurium

Class

Dose
Onset
Recovery TOF

Releax w/ suggamadex?

Broken down
by
Reversed with

A

The newest benzylisoquinolinium non-depolarising muscle relaxant is gantacurium, which is currently undergoing phase III trials in the U.S. When given as a dose of 1.8-4 ED95 it has a rapid onset of action of 90 seconds with spontaneous recovery of the train-of-four (TOF) ratio to 0.9 in approximately 10-14 min (intermediate duration).

Steroidal neuromuscular blocking relaxants are most likely to be reversed with sugammadex (rocuronium, vecuronium and pancuronium).

Gantacurium is broken down non-enzymatically to inactive metabolites by the endogenous amino acid, L-cysteine, in plasma. This amino acid conjugates with the central double-bond carbons in gantacurium causing alkaline hydrolysis. The exogenous administration of L-cysteine immediately reverses the effects of a dose of gantacurium.

It has been developed as a possible replacement for suxamethonium.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Features organophosphate poison

Rx of organophosphate

A

This leads to excess cholinergic activity and features that include:

Vomiting
Diarrhoea
Rhinorrhoea
Salivation
Constricted pupils
Convulsions
Muscle fasciculation
Muscle paralysis (including respiratory)
Apnoea
Death.

Treatment consists of atropine to antagonise the cholinergic effects, and oxime (pralidoxime) to limit the inhibition of cholinesterase and diazepam to prevent seizures.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Trac metabolites

elim how

A

Hoffman degradation - 30-70% non-enzymatic spontaneous process which is temperature and pH dependent. Reduced at low temperature and pH conditions.
Ester hydrolysis - catalysis by non-specific plasma esterases.

principal metabolites are
laudanosine,
tetrahydropapaverine and
a monoquaternary alcohol metabolite

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

NDMR

Where& what do they act
specifically

What does blockade cause

A

inhibit the actions of acetylcholine

Neuromuscular junction

binding competitively

α-subunit

nicotinic acetylcholine receptor

post-junctional membrane.

They also have effects on prejunctional receptors that modulate acetyl choline release.

Fade during tetanic stimululi or train of four

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
What is the NMJ
Connection motor neuron & skeletal muscle fibre - NT ACh Terminal axon - fas Aalpha motr neurone lies in groobe in middle surface m,uslce fibre it innervates Most muscles - single terminal axon innervates a single muscle fibre Some - intra ocular, intrsic laryngeal & some facial muslce - fibre innervation - multiple slower Ay motor fibres Post synaptic membrane - folded - form peak & trough - on surface Membrane over peak - ach recpt trough contrain achesterase AP arrives - depol influx ca Ca - combine protein faciltate fusion vesicle - containing ach in presynamptic membrane Central ion chanel of receptor opens- allow movement Ions across membrane Movement of these ions allows generation of a min end plate potential Summation of several end plate potentials continue until threshold potential reached at this point voltage gate Na channel open rapid depol cell memnbrane Depol - spreads thru fibre - reaches SR cause Ca release * contraction
26
How is Ach broken down
Acteylchonilestarse in torugh of post synaptic membrane bind to either ester group Ach molecule or the quaternary ammonium group choline removed recycle - acetalyed enz hydrolysed to acetic acid
27
Classify drugs
Prevent synthesis Prevent release Deplete stores Block receptoor
28
How is ach formed
Combineation choline & acteyl coa - catlysed by enz choline acetyl transferase Syhtsises in acoplasm of motor nuerone 0 tprot to terminal axon - stored vesicle Choline derive diet - recycle breakdown other acteylchol molecu
29
Hemicholinum
Prevent acetylcholinse synthesis Synthetic compound prevent uptake choline into nerve ending - reduce synth
30
Mg & aminoglycoside
Inhib ca entry in synaptic terminal | prevent release AcH
31
Botox
Binds irreversibly -> nicotnic nerve terminals to prevent ach release
32
Tetanus toxin
Depletes stores - rendering paralsyed
33
Depolarising muscle blockade Sux what is it phsyical prop
Suxamethonium 2 ach molecules join by ester link Rapid profound muscle releax facil intub trach praylsis short procedure modify effect sz - ect Colourless soln cl salt 50mg.ml store 4C prevent det destroyed alkaline pH - not mix thio
34
Sux MOA Metab/bbreakdown
MOA bind revs to ach recept on post synaptic - cause depol membrane Mechaism breakdown - depol prolong create& create membrane potential not allow generation urther potent - relax Broken down bytylucholinesterase - plasma but not NMJ Lack plasma chol NMJ - explain prolong duration action Hydrolysis sux by plasma cholinseterase - produce weak active metab - succinylmonocholine & choline - further hydrolsed by pl cholinest succinic acid +; choline Admin dose sux - 20% reach NMJ rapid metab 2-10% excrete urine
35
Non depol MR
Competitive antago at NMJ - bind a subunit of nictonic receptor on post junctional membrane
36
Classify NMDR
Aminosteroidal Roc Vec panc Benzylquionloium trac mivac tubocurarine Futrher class duration Mivac - v short trac & roc - intermed Panc long
37
How NDMR metabolised
Mivac & Trac - hydrolysed plasma Roc & vec - vary degree by liver Unmetab exrete urine / bile
38
How is atracurium metabolised
Hoffman elim Body ph & temp - spont degrad Laudonise & quat monacrylate Slowed by acidosis & hypoterhm Ester hydol ~60% Non specific esterases - unrelated to plsma cholinester Prod laudanoise, quaternary alcohol & acid Acclearted u acidosis clinca rang pH - unlikely diffrence
39
Laudonisine? active
No nm block prop terti amine t1/2 2-3h doesnt reach level cause epileptiform movements after days infusion
40
Side effects trac
Histamine rlease - loc system System -cvs/ resp - hypotension / bronchospasm Critical illness myophaty
41
Whats cis trac
Trac mix 10 steroisomer cause it has 4 chiral molecules Cistrac - more favourable s/e - ptential his relase low How does Cistrac compare to trac 3-4 peotency - intubate dose /2mg/k Predom Hofmann no active metabolites safe reanl and hepatic failure
42
Trac intubating dose
.5mg/kg | onset time - impeved - larger dose
43
Roc intubating dose
.6mg/kg - 120s to intubating conditions if 1mg kg - intubating cond 60s
44
Side effects of aminosteroidal
No effect CNS - Dont icrease IOP vec & roc - lim cvs Pan - trchycardia - vagolytic Akk cause respparlayis- unlike be\ylquin - dont cause his relase induced bspams
45
Abx effect on NDMR
amino glycose Tetracylice - prolonf Compete w/ calciyum - prevent release ach
46
Other drugs affect ndmr
Volatile -reduce nt nmj - depress somatic relfex in cns Prolong block Li block Na channel Local Block Na channel Ca channel antag reduce ca infulx into nerve termninal - reduce ach release
47
Physiological infleunces on NMB
hypothermia, hypermag, hypokalaemia, acidosis prolong NMB Hypoeterhm red emtab Mg reduce ach - compete ca K low - reduce rmp
48
Proerty ideal
Phsysical - cheap wwater sol long shelf life no spec sotarg ``` pk Short duation - predicat rever non cumlative infisable where neccesary completley metab into non active matolites not affect hepatic / renal failure ``` PD properties Rapid onset high potency no cv /resp side effects safe in children non depol moa
49
Suxamethonium partial block
Phase 1 Equal reduced twitch height to TOF S Sustain reduced tetanic count -no fade or post teatnic potention lARGE DOSE SUX - PHASE 2 BLOCK MAY OCCUR FEATURES NOn depol blokc replace depol m,ech uncreat - pre or post junc mmoudlation
50
Sux side effects x8
1. Myalgia 2. arryhthmyia - brady 3. Hyperkalamei 0.5 rise 4. IOP - 10-15mmhg (offset by thio) 5. Intragastic pressure - 10cm - offset rise LOes tone 6. Anaphlyaxis 7. Sux apnoea 8. MH
51
What are the CI to sux
Raise pottasium traume muscle hx mh sux penoe burns of >10% / scord trauma avoid 24 hours ~18months post injury Muslce disease
52
What is MH
Life threatning AD Suscplitle indivuse Uncontrol skel muslc metab Features 1. Masseter spasm 2. Muscle rigidity 3. Rising temp >2C /h 4. Rising etco2 First symp mmay be unexplain tachy O2 demaind outsip supply o2 sats may fall Blood result - elvated Ca, K CK, Myoglov Metabolic acidosis ARF
53
How is MH manged
``` Withdraw trigger Dantrolene 2-3mg/kg Supportive Acidosis cooling resp support hpyervent Inotropes ``` HyperK correct ARF & DIC rx ICU
54
Dantrolene
Muslce releax - uncolple excite contract process - prevent ca release 10%
55
Pathophys MH
Mutation gene coding rayanodine receport chr 19 | Located SR - crucial in calcium control
56
Tests for MH
Caffeine haltothane contracture standard MH bx muscle 2% halothane & caffine tension muscle measured -> contracture occurs sucel susceptible , equiv, non
57
Sux apnoea
Genetically succep Decrease plasma pseudocholisterase activity Sux not broken down - prolong block paralysis & apnoea genetic vary ``` acquired liver / cardiac fail renal disease pregnance thyortox malnutrition burns plasmprhoesis drug inhib cholist ```
58
Genetic sux apneoa
Chr 3 e1 locus single aa sub - pseudochol act Several AR id - degree inhbi Dibucaine & fluoride - describe vary 4 allel noraml eu Dibu res Ea Flouride resist Ef Silent Es 96% homozyous for normal 0.001 homzygous silent gene - no enz fux Dibuc fl numbers - denote percent inhib High number - better function Indiv - homozygote any alles or allele can exist in hetro combo homzygo silent & atypical - paralysis can last 4 hours homzygo flouride res - 2 hours heterzygo - abonram 4% mild prolong ~10m
59
Manage sux apneoa
Anesthesia & vent support tuntwil warn | FFP given contains plasma cholesterase
60
What type of ach receptors are there
Nicontic Ligand gated Ion channel Muscarinic - G pro rec - second messengers
61
Describe the nicotinic structure
``` Nicotnic receptor - membrane prtein - 5 subnuints 2 Alpha one b one e one delta ``` Binding sites - on two Alp subnit One ach bind to Alp - increase affinity ach at other Alpha As binds - confromation change - cnetral chenll in receptor to open Channel allows passage Na ion & other cation thru cell membrane = despolirisation & generation AP
62
Acetylcholinestrase enz
Esteratic & anionic bind site anionic site bind - pos wuater ammon esteratic bind acetate
63
what happens ach after synthesis
Active transport moves ach into synaptic vesicles store until release - rsponse to AP Vesicle contains 10000 acetyl choline molecule 200 vecels relase after every Ap Once release - enter synapse bind to receport to prop AP After bind - hyrolsyse ach -> choline & actate
64
Ach inhbitor
Anticholinesterase Antag acetylcholinesterase enzy @ NMJ inhib breakdown ach Increases synatpic ach - dspalce of NM block agent from recpeort - resotres transmisson Reberasel Clin practice - MG
65
Disadvantages
Effects are non specific nmj ``` also seen at muscarinc recptors - increase ach= bradcardia arryhtmia brocnhosapsm n+V Gut motilisty salivation ``` Prevent s/e - common given anticholingergic at same time achase inhib
66
Classify inhibitors
competitive antago - edophonium - dx mg rapidly transienty impove muscple power Forma barbamalted enzyme nostgime pyrdiostimine Carabmylated complex w/ acheesterase Irrev inact ach Organophs - no role clin preac insecicde chem weapon First two - stuc similar both qaurternary ammon comp
67
How does neostimge act to reverse NMB
Ach'esterase inhib Incrase Ach at nmj - prevent breakdown by achase Quarternary amine - struct sim to ach = can bind to achease cationic part - bind to anionic site Terminnl carbon atom bind to esteartic site Phenol group - breaks leaving acheserase enzyme occupied fragments Imparis ability ach'ase to metab ach - allow acummulate - dispalce Non depol MR Compet bound to achR Transmissio restored - paralysis reversed
68
How do organophosphates work
Phosphorylate the esteratic site of eachesase -enz Inhib actions enzyme - Complex - stable unlike formed w/ neostimge - resistant to hydrolyis
69
Toxic effects of oragnophosphates How do you treat poisoning
muscle wekaness polyneuropathy Resp failure Cholinergic crisis - musc & nic Practice - Rx posoining rely prodcution of new ach'ase enzyme Supportive Rx - interim Vent Atropine - counteract muscarinic effects Pralidoxime - promotes hydroylsis of phosophrylated complex
70
Sugammadex What is it Whast structure is it How is it modified
SRBA Reversal - aminostreodial modified gamma -cyclodextrin Cycloex oligosacchardies - ube like Lipophillic core - water solube hydrophilic exterior Y cyclodextrin - modified - natural form 8 glucopyarnose units They increase cavity size - encapsulate roc in cavity When administered - encapsulates roc in core - render unavailable to bind to achrecp Kidney rapidly excrete complex
71
Advantages sugammadex
Main advant - reversal - not rely inhib ach'ase Not caus brady, secreti, gi motil - brocho - neostimgine unopposed muscaric Admin indic & antimusc not have to admin - drug error Fast onset - short duration alretantive to sux - number undesirable side effects
72
Suggammadex with other
Has affinity for others -vec less than that of roc Vec mor potent - less molecule aqt NMJ - equiv block - Encapsulate @1:1 ratio reverse vec despite reduced ffinity - fewer molecules to bind
73
Disadvantages
1. Cost 2. Not recomm - sever impairment GRF <30 Fluclox fusidic acid - may dspalce - reoccurence block Decrease progest in OCP - act as missed pill dysgeusia - ADR - metal taste
74
Dose sugammadex
Monitoring - to clalc prior to admin If 2 twitches - dose is 2/kg if 2 as PTC 4/kg Immed reverse - 16mg/kg Multiple vials 80kg - dose 1280mg
75
Anticholinergics eg where do they act which are natural which doesnt cross bbb
Hyoscine Atropine Glycopyrrolate act on muscarinic receptors little activity at the nicotinic Hyoscine and atropine - naturally occurring esters. Glycopyrrolate synthetic quaternary amine not X bbb Hyoscine hydrobromide greatest antisialogogue properties. Cause central anticholinergic syndrome readily crosses the blood brain barrier. characterised by hallucinations, excitement and ataxia. Note, hyoscine butylbromide does not cross the blood brain barrier significantly.
76
What is dibucaine What does it do Ca you rule out sux apneoa with a dibucaine nmber of 70
Dibucaine is a local anaesthetic agent that inhibits plasma cholinesterase. Dibucaine inhibits normal variant of the enzyme by 80% but other variant forms of plasma cholinesterases are inhibited less effectively. A patient homozygous for the fluoride-resistant genotype may still have a dibucaine number of 70 but with reduced plasma cholinesterase activity.
77
Reduced plasma cholinesterase activity acquired:
``` Pregnancy Renal failure Hepatic disease Malignancy Concomitant drug use. ``` In renal failure plasma cholinestrase levels are reduced by haemodilution and reduced liver production.
78
Central anticholinergic syndrome What causes it How is it diagnosed How is it treated Why does this drug work What are the symptoms
Decrease in the inhibitory acetylcholine activity in the brain. Central cholinergic sites are occupied by specific drugs / insufficient release of acetylcholine. Central anticholinergic syndrome during recovery is essentially a diagnosis of exclusion and can be confirmed only after resolution of symptoms with physostigmine (0.03- 0.04 mg/kg). Physostigmine is well abosorbed by gut The incidence of CAS is as high as 8-10%. The anticholinesterase of choice is physostigmine as this is the only anticholinergic agent used clinically that crosses the blood brain barrier because it is a tertiary amine (hydrophobic). Pyridostigmine, neostigmine and edrophonium are quaternary amines. Symptoms include: ``` Agitation Seizures Restlessness Hallucinations Disorientation, or Signs of depression such as stupor, coma and respiratory depression. ```
79
Ecothiophate What is it What are its uses When applied topically what does it do?
Ecothiophate ``` Parasympathomimetic agent Irreversible acetylcholinesterase (AChE) inhibitor ``` also inhibits butrylcholine (plasma cholinesterase). It is used as an ocular antihypertensive in the treatment of chronic glaucoma. When applied topically, constriction of the sphincter pupillae and ciliary muscles leads to miosis and blocking of the accommodation reflex. It reduces intraocular pressure, if elevated, by facilitating aqueous humour outflow.
80
Sux apnoea how many genotype how many allele what are the allels whats the ongest durn path causes of acq sux apnoea phys causes
10 geno 4 allele silent atypical Fl resistan Normal Longest - homozygous silent heterzy silent atyp path cuases - hfail , rfail, liver fail, HYPERthyroid, Canc phys preg- drug induced second drug act substrate or inhibitor - metoclop to pl cholinest
81
Mivacurium
Revesral poss with edophonium -> increase Ach release as mivac is metab pl cholinesterase (neostigmine inhib)
82
Donepezil
reversilbe - inhibitor acetylcholinsetras - od dose alzhemier
83
ecothiopate
organophosp - narrow anle glaucoma
84
Edrophonium
aid dx Mg inact - achesterase - weak electrosatic bond block active site faster onset - neostigmine fewer muscarinic side effects casues in ach relase quatern amine Doesnt x bbb 65% excr unchanged rest - glucorn in liver
85
TOF | is what
4 supramax stim lasting .2ms 2hz no twich = 100% 1 =90% 2 =80% 3 =75%
86
PTC useful
No twich tof ``` 5s 50hz stim 3sec pause pluse stim 2hz ptc recorded 15=2tof ```
87
Hyoscine x bbb glyco excretion what isomer of atropine is active
Yes 80% unchanged in urine Atropine = may transient brady partioal agonist effect at musc reseptor only L is active (same w/ hyoscine)
88
Gallamine affect HR why
1st synthetic muscle relaxant increase HR - second cardiac musc recpot block / sns stim like panc